ATOS Atossa Therapeutics Inc revenue, earnings and financials
For the quarter ended June 30, 2026, Atossa Therapeutics Inc reported revenue of n/a, net income of −$8.49M and diluted EPS of −$0.95; for the fiscal year ended December 2025 revenue was n/a.
ATOS annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$37.1M, net income −$34.8M (margin n/a), EPS −$4.04
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$27.6M, net income −$25.5M (margin n/a), EPS −$3.04
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$31.4M, net income −$30.1M (margin n/a), EPS −$0.24
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$27.7M, net income −$27.0M (margin n/a), EPS −$0.21
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$20.5M, net income −$20.6M (margin n/a), EPS −$0.18
ATOS quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$8.49M, EPS −$0.95
- Quarter ended Mar 31, 2026: revenue n/a, net income −$9.59M, EPS −$1.11
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$10.9M, EPS −$2.21
- Quarter ended Sep 30, 2025: revenue n/a, net income −$8.69M, EPS −$0.07
- Quarter ended Jun 30, 2025: revenue n/a, net income −$8.42M, EPS −$0.98
- Quarter ended Mar 31, 2025: revenue n/a, net income −$6.72M, EPS −$0.78
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$6.35M, EPS −$2.88
- Quarter ended Sep 30, 2024: revenue n/a, net income −$7.23M, EPS −$0.06
- Quarter ended Jun 30, 2024: revenue n/a, net income −$6.05M, EPS −$0.05
- Quarter ended Mar 31, 2024: revenue n/a, net income −$5.88M, EPS −$0.05
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$7.75M, EPS −$0.06
- Quarter ended Sep 30, 2023: revenue n/a, net income −$6.23M, EPS −$0.05
- Quarter ended Jun 30, 2023: revenue n/a, net income −$9.83M, EPS −$0.08
- Quarter ended Mar 31, 2023: revenue n/a, net income −$6.28M, EPS −$0.05
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$7.49M, EPS n/a
- Quarter ended Sep 30, 2022: revenue n/a, net income −$8.01M, EPS n/a
- Quarter ended Jun 30, 2022: revenue n/a, net income −$6.67M, EPS n/a
- Quarter ended Mar 31, 2022: revenue n/a, net income −$4.79M, EPS n/a
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$4.83M, EPS −$0.04
- Quarter ended Sep 30, 2021: revenue n/a, net income −$5.20M, EPS −$0.04
ATOS cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$29.8M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$21.0M, share buybacks $0
- Fiscal year ended Dec 2023: operating cash flow −$20.9M, share buybacks $1.48M
- Fiscal year ended Dec 2022: operating cash flow −$20.8M, share buybacks $0
- Fiscal year ended Dec 2021: operating cash flow −$16.5M, share buybacks n/a
ATOS balance sheet
- Jun 30, 2026: cash $26.1M, total assets $32.3M, total liabilities $5.45M, shareholders' equity $26.8M
- Mar 31, 2026: cash $31.7M, total assets $37.9M, total liabilities $7.46M, shareholders' equity $30.5M
- Dec 31, 2025: cash $41.3M, total assets $47.6M, total liabilities $8.26M, shareholders' equity $39.4M
- Sep 30, 2025: cash $51.8M, total assets $58.0M, total liabilities $8.23M, shareholders' equity $49.8M
- Jun 30, 2025: cash $57.9M, total assets $64.5M, total liabilities $6.82M, shareholders' equity $57.7M
- Mar 31, 2025: cash $65.1M, total assets $70.7M, total liabilities $5.43M, shareholders' equity $65.3M
- Dec 31, 2024: cash $71.1M, total assets $76.4M, total liabilities $4.97M, shareholders' equity $71.5M
- Sep 30, 2024: cash $74.8M, total assets $79.5M, total liabilities $5.80M, shareholders' equity $73.7M
Is ATOS profitable?
No. Atossa Therapeutics Inc lost $37.7M over the last four quarters.
What is ATOS's EPS?
Diluted earnings per share over the last four quarters were −$4.34; −$0.95 in the latest quarter.